1. Cell Cycle/DNA Damage
    Autophagy
    Antibody-drug Conjugate/ADC Related
  2. DNA Alkylator/Crosslinker
    Autophagy
    DNA/RNA Synthesis
    ADC Cytotoxin

Mitomycin C (Synonyms: Ametycine)

Cat. No.: HY-13316 Purity: 98.51%
Data Sheet SDS Handling Instructions

Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

For research use only. We do not sell to patients.
Mitomycin C Chemical Structure

Mitomycin C Chemical Structure

CAS No. : 50-07-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $58 In-stock
5 mg $53 In-stock
10 mg $70 In-stock
50 mg $220 In-stock
100 mg $300 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    Mitomycin C purchased from MCE. Usage Cited in: Sci Rep. 2017 Jun 30;7(1):4469.

    In order to normalize the potential effect of cell proliferation, Mitomycin C is added to the culture media to make the cells uniformly arrested. The results show that all migration cell indexes reduced after adding Mitomycin C than those observed without Mitomycin C. Knockdown of RAD51-AS1 still inhibits cell migration (A) and invasion of SKOV3, SKOV3.ip and HO8910 cells (B), while overexpression of RAD51-AS1 only increased cell invasion capacity of the OVCAR3 cells, not in the Hey cells (C).

    Mitomycin C purchased from MCE. Usage Cited in: Exp Cell Res. 2016 Feb 15;341(2):157-65.

    Curcumin inhibits the migration of BCPAP cells. Migration of cancer cells is assayed by wound-healing assay. Cells are cultured to nearly confluent cell monolayer and pretreated with Mitomycin C (10 μg/mL) for 2 h, followed by either DMSO or different dosages of curcumin for 6 h, before cells are wounded using yellow pipette tips. The cells are washed with PBS, and cultured for additional 24 h at 37 °C. (A) Photographs are taken after wound initially made and healing for 24 h. Data are represent
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

    IC50 & Target

    DNA synthesis[1]

    In Vitro

    The HCT116 (p53-/-) cells are minimally sensitive to either Mitomycin C or TRAIL alone. However, surprisingly, combination treatment with MMC and TRAIL decreases cell viability significantly. Although Mitomycin C and TRAIL alone are moderately effective, Mitomycin C substantially enhances the effect of TRAIL on suppression of the cell proliferation. Mitomycin C and TRAIL treatment alone induces 9.5% and 35.0% apoptosis, respectively. However, combination treatment with Mitomycin C and TRAIL enhances apoptosis to 66.6%[1]. Mitomycin C is a cytotoxic chemotherapeutic agent that causes DNA damage in the form of DNA cross-links as well as a variety of DNA monoadducts and is known to induce p53[2].

    In Vivo

    Mice bearing xenografted HCT116 (p53-/-) colon tumors and HT-29 colon tumors are treated with Mitomycin C (i.p., 1 mg/kg) and TRAIL (i.v., 100 μg) every other day. Animals are treated with 10 consecutive cycles of the combination therapy regimen. The combination therapy suppresses tumor growth significantly and does not impact the weight of the mice, indicating that the therapeutic combination of Mitomycin C and TRAIL is well-tolerated and has anti-tumor activity in vivo[1]. Intravesical Mitomycin C instillations has an effect on body weight that is not observed in normal, NaCl instilled or Epirubicin instilled rats. After 3 consecutive weekly instillations of 1 mg/mL Mitomycin C there is almost no weight gain, whereas rats in the other 3 groups has a statistically significant weight gain compared with MMC treated rats[3].

    Clinical Trial
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.9911 mL 14.9553 mL 29.9106 mL
    5 mM 0.5982 mL 2.9911 mL 5.9821 mL
    10 mM 0.2991 mL 1.4955 mL 2.9911 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay
    [1]

    Mitomycin C is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1].

    Colon adenocarcinoma HCT116 and HT-29 human colon cancer cells are used. The CellTiter-Glo Luminescent Cell Viability Assay is used to measure cell viability, which use a unique, stable form of luciferase to measure ATP as an indicator of viable cells, and the luminescent signal produced is proportional to the number of viable cells present in culture. Cells are pretreated with Mitomycin C (5 μM) for 12 h or 24 h, and then exposed to different concentrations of TRAIL for 12 h. An equal volume (100 μL) of CellTiter-GloTM reagent is added and the solution is mixed gently for 2 min on an orbital shaker. Mixture is incubated at room temperature for 10 min to allow luminescent signal to stabilize, and then imaging is performed using the Xenogen IVIS system to quantify the cell viability[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1][3]

    Mitomycin C is prepared in saline (0.9% NaCl).

    Mice[1]
    Four- to 6-wk-old NCr nude mice are treated with Mitomycin C (1 mg/kg) by intraperitoneal injection for 24 h, followed by one intravenous dose of purified rhTRAIL (100 μg). As a negative control, a subset of the mice are injected (i.p. and i.v.) with saline (vehicle) at the same frequency of treatment. Animals are treated for 3 consecutive weeks. The tumor size is monitored every week using caliper measurements of the tumor volume.
    Rats[3]
    Young adult female Wistar rats at age 13 weeks with a median weight of 217 g (range 187 to 255) are randomized into 4 groups of 10 each, namely a normal group with no instillations, an NaCl 0.9% or placebo group that received instillations with the solvent of the chemotherapeutic agents, an Mitomycin C (1 mg/mL) group and an Epirubicin (1 mg/mL) group. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    334.33

    Formula

    C₁₅H₁₈N₄O₅

    CAS No.

    50-07-7

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: 30 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 98.51%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Mitomycin C
    Cat. No.:
    HY-13316
    Quantity: